Kevin DeGeeter
Stock Analyst at Ladenburg Thalmann
(2.83)
# 1,588
Out of 5,180 analysts
44
Total ratings
38.89%
Success rate
50.75%
Average return
Main Sectors:
Stocks Rated by Kevin DeGeeter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DCOY Decoy Therapeutics | Initiates: Buy | $30 | $6.76 | +343.79% | 1 | Jan 23, 2026 | |
| NXTC NextCure | Upgrades: Buy | $18 | $9.35 | +92.62% | 1 | Nov 7, 2025 | |
| ORIC ORIC Pharmaceuticals | Initiates: Buy | $15 | $12.19 | +23.05% | 2 | Jul 8, 2025 | |
| CRDF Cardiff Oncology | Initiates: Buy | $19 | $1.55 | +1,125.81% | 1 | Jul 8, 2025 | |
| NVCR NovoCure | Initiates: Buy | $30 | $10.36 | +189.58% | 4 | Jul 8, 2025 | |
| ANTX AN2 Therapeutics | Initiates: Outperform | $22 | $3.46 | +535.84% | 1 | Apr 19, 2022 | |
| PSNL Personalis | Maintains: Outperform | $30 → $24 | $6.24 | +284.62% | 4 | Feb 25, 2022 | |
| FLGT Fulgent Genetics | Maintains: Outperform | $141 → $125 | $15.63 | +699.74% | 3 | Jan 25, 2022 | |
| MDXH MDxHealth | Initiates: Outperform | $18 | $2.29 | +686.03% | 1 | Nov 29, 2021 | |
| SERA Sera Prognostics | Initiates: Outperform | $19 | $1.92 | +889.58% | 1 | Nov 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.24 | - | 1 | Oct 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $79 | $154.35 | -48.71% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $25.13 | - | 2 | Jun 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $2.85 | +777.19% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,800 | $3.77 | +47,645.36% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $30.55 | - | 2 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.07 | - | 1 | Jan 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.45 | - | 4 | Dec 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,500 | $2.61 | +57,371.26% | 1 | Jul 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $1.13 | +79,546.02% | 1 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $8.09 | - | 2 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $165 | $16.62 | +892.78% | 1 | Jun 6, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $4.36 | - | 5 | Feb 8, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $1.52 | - | 2 | Jan 4, 2017 |
Decoy Therapeutics
Jan 23, 2026
Initiates: Buy
Price Target: $30
Current: $6.76
Upside: +343.79%
NextCure
Nov 7, 2025
Upgrades: Buy
Price Target: $18
Current: $9.35
Upside: +92.62%
ORIC Pharmaceuticals
Jul 8, 2025
Initiates: Buy
Price Target: $15
Current: $12.19
Upside: +23.05%
Cardiff Oncology
Jul 8, 2025
Initiates: Buy
Price Target: $19
Current: $1.55
Upside: +1,125.81%
NovoCure
Jul 8, 2025
Initiates: Buy
Price Target: $30
Current: $10.36
Upside: +189.58%
AN2 Therapeutics
Apr 19, 2022
Initiates: Outperform
Price Target: $22
Current: $3.46
Upside: +535.84%
Personalis
Feb 25, 2022
Maintains: Outperform
Price Target: $30 → $24
Current: $6.24
Upside: +284.62%
Fulgent Genetics
Jan 25, 2022
Maintains: Outperform
Price Target: $141 → $125
Current: $15.63
Upside: +699.74%
MDxHealth
Nov 29, 2021
Initiates: Outperform
Price Target: $18
Current: $2.29
Upside: +686.03%
Sera Prognostics
Nov 19, 2021
Initiates: Outperform
Price Target: $19
Current: $1.92
Upside: +889.58%
Oct 1, 2021
Downgrades: Perform
Price Target: n/a
Current: $2.24
Upside: -
Aug 24, 2021
Maintains: Outperform
Price Target: $75 → $79
Current: $154.35
Upside: -48.71%
Jun 29, 2021
Downgrades: Perform
Price Target: n/a
Current: $25.13
Upside: -
May 27, 2021
Initiates: Outperform
Price Target: $25
Current: $2.85
Upside: +777.19%
Mar 2, 2021
Initiates: Outperform
Price Target: $1,800
Current: $3.77
Upside: +47,645.36%
Jan 11, 2021
Downgrades: Perform
Price Target: n/a
Current: $30.55
Upside: -
Jan 5, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.07
Upside: -
Dec 8, 2020
Downgrades: Perform
Price Target: n/a
Current: $3.45
Upside: -
Jul 1, 2020
Initiates: Outperform
Price Target: $1,500
Current: $2.61
Upside: +57,371.26%
Apr 8, 2020
Initiates: Outperform
Price Target: $900
Current: $1.13
Upside: +79,546.02%
Aug 9, 2017
Upgrades: Buy
Price Target: n/a
Current: $8.09
Upside: -
Jun 6, 2017
Initiates: Buy
Price Target: $165
Current: $16.62
Upside: +892.78%
Feb 8, 2017
Upgrades: Neutral
Price Target: n/a
Current: $4.36
Upside: -
Jan 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $1.52
Upside: -